A Phase I/2 Study of Ixazomib for Chronic Graft-Versus-Host Disease (cGVHD) Prophylaxis After Allogeneic Transplantation (alloHCT).
Biology of Blood and Marrow Transplantation - Netherlands
doi 10.1016/j.bbmt.2018.12.213
Full Text
Open PDFAbstract
Available in full text
Date
March 1, 2019
Authors
Publisher
Elsevier BV